21-329 Phase II
A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors
Search Cancer Clinical Trials
Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
28 results
22-173 Phase I
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 as a Single Agent and in Combination Therapy in Subjects With Selected Advanced Solid Tumors
19-572 Phase II
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
23-423 Phase I
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Pembrolizumab in Patients with Select Advanced Cancers
22-326 Phase II
A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas
22-619 Phase II
A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor Therapy
21-077 Phase II
A Phase II study of PD-1 blockade with or without LAG-3 inhibition in combination with infliximab for the treatment of metastatic melanoma and prevention of adverse events
23-286 Phase II
A Phase II Study of the Interleukin-6 Receptor Blocking Antibody Sarilumab in Combination with Ipilimumab, Nivolumab and Relatilimab in Patients with Unresectable Stage III or Stage IV Melanoma
19-499 N/A
An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-la Roche LTD sponsored Atezolizumab study IMBRELLA B)
22-614 Phase I
An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Showing 11 - 20 of 28 results